The global next generation sequencing market is anticipated to reach USD 14.0 billion by 2024, according to a new report by Grand View Research, Inc. Growing adoption of next generation sequencing techniques for prognosis and treatment monitoring of different chronic diseases such as cancer and other pathogenic infections is one of the high impact rendering driver for progress in this industry.
Application of genome and exome sequencing in the field of cancer research for companion diagnostics and biomarker development are expected to contribute towards the growth of this market throughout the forecast period.
Moreover, anticipated exponential decrease in the prices of genome sequence determination coupled with the launch of novel platforms and whole genome sequencers by major market players is expected to have a significant positive impact on the market penetration of various NGS applications.
View
summary of this report @ http://www.grandviewresearch.com/industry-analysis/next-generation-sequencing-market
Further key findings from the report suggest:
·
Out of the different applications served by NGS
technology, Oncological applications accounted for the dominant share owing to
phase-resolved and unambiguous results obtained by using single assay systems,
and analysis program. However, the use of HLA typing in gaining insights for
organ rejection, organ matching, and immune disorders by understanding
intricacies of less accessible genetic sequence structures is anticipated to
provide scientists with new avenues for medical research over the forecast
period.
·
Depending on the approaches by which the number
of base pairs can be determined in a given sequencing read cycle, the
technologies can be segmented as targeted sequencing & resequencing, whole
genome, and whole exome sequencing. Targeted resequencing dominated the market
with a revenue share of over 70%owing to the benefits associated with
implementation of the technique such as lower turnaround time and more
manageable data sets.
·
Amongst workflow steps involved, NGS data
analysis encompasses the final phase of data storage and analysis of large
amounts of sequenced data which is generated. This segment is expected to
witness growth in demand in tandem to growth in demand for NGS through to 2024.
·
Academic R&D usage of NGS accounted for the
largest share with respect to market revenue by end uses and is anticipated to
maintain its dominance owing to higher adoption of this technology and
platforms in university projects related to molecular, genetic & proteomic
biology, and drug discovery/development.
·
North America dominated the market in 2015,
generating over 46% of total revenue. Presence of the key participants
operating in this region which are involved in development of novel algorithms
and software in order to enhance data analysis is attributive for the large
share of North America in industrial revenue. Demand for whole genome
sequencing services for disease progression monitoring is also expected to
drive industrial progress.
·
Asia Pacific is estimated to witness the fastest
growth over the forecast period owing to the expected routing of a considerable
portion of whole genome sequencing requirements through a couple of the world’s
largest sequencing facilities present in the region and potential presence of
unmet demands by the research institutions with respect to sequence
determination techniques and data analysis algorithms.
·
Key players operating in the next generation
sequencing market include Illumina Inc., Agilent Technologies, Biomatters Ltd.,
Bgi (Beijing Genomics Institute), Pacific Biosciences, Dnastar., Clc Bio (Qiagen),
454 Life Science Corp. (Roche), GATC Biotech Ag, Knome Inc., Life Technologies
Corp. (Thermo Fischer Scientific), Genomatix Software GmbH, Macrogen., Partek.,
Oxford Nanopore Technologies Ltd., and Perkin Elmer.
·
This market is witnessing high level of
competitive rivalry, consequently leading to constant endeavors carried out by
the prominent players in order to maintain the position and share in the
industry. These endeavors include launch of novel products, providing services
and products in different economies across the globe, broadening of the product
portfolio with respect to various application areas, and acquisition of the
smaller entities in attempts to enhance product portfolio. For instance, Qiagen
acquired solutions unit of Enzymatics in order to enhance the product portfolio
with respect to reagents needed in preparatory steps.
Browse All Reports of
this category @ http://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented next generation sequencing market on the basis of application, technology, workflow, end-use, and region:
Global Next Generation Sequencing Outlook, by Application (Revenue, USD Million, 2013 - 2024)
·
HLA Testing
·
Prenatal Testing
·
Oncology
·
Idiopathic Diseases
·
Infectious Diseases
Global Next Generation Sequencing Outlook, by Technology (Revenue,
USD Million, 2013 - 2024)
·
Whole Genome Sequencing
·
Whole Exome Sequencing
·
Targeted Sequencing and Resequencing
Global Next Generation Sequencing Outlook, by Workflow (Revenue, USD
Million, 2013 - 2024)
·
NGS Pre-Sequencing
·
NGS Sequencing
·
NGS Data Analysis
·
NGS Primary Data Analysis
·
NGS Secondary Data Analysis
·
NGS Tertiary Data Analysis
Global Next Generation Sequencing Outlook, by End-use (Revenue, USD
Million, 2013 - 2024)
·
Academic Research
·
Clinical Research
·
Hospitals & Clinics
·
Pharma & Biotech Entities
·
Other users
Next Generation Sequencing Regional Outlook (Revenue, USD Million,
2013 - 2024)
·
North America
·
U.S.
·
Canada
·
Europe
·
Germany
·
UK
·
Asia Pacific
·
China
·
Japan
·
Latin America
·
Brazil
·
MEA
·
South Africa
No comments:
Post a Comment